DM
BEAM icon

Deerfield Management’s Beam Therapeutics BEAM Stock Holding History

Deerfield Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-877,809
Closed -$17.1M – 129
2025
Q1 		$17.1M Buy
+877,809
New +$23M 0.34% 54

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management's BEAM Position: Q2 2025 in Review

Deerfield Management sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 877,809 shares — an estimated $17.1M sold.

Deerfield Management first reported a position in BEAM in Q1 2025 and held it in 1 quarter. The position peaked at $17.1M in Q1 2025. 216 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • Deerfield Management reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Deerfield Management sold 877,809 Beam Therapeutics shares in Q2 2025, an estimated $17.1M.
  • Deerfield Management first reported a position in Beam Therapeutics in Q1 2025 and held it in 1 quarter.
  • Deerfield Management's Beam Therapeutics position peaked at $17.1M in Q1 2025.
  • 216 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Deerfield Management's 13F filing for Q2 2025, filed 14 Aug 2025.